CYP17 POLYMORPHISMS AND PROSTATE CANCER OUTCOMES

被引：0
|
作者：
Wright, Jonathan L.
Lin, Daniel W.
Kwon, Erika M.
Kolb, Suzanne
Feng, Ziding
Koopmeiners, Joseph
Ostrander, Elaine A.
Stanford, Janet L.
机构：
来源：
JOURNAL OF UROLOGY | 2009年 / 181卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(09)62164-9
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
2142
引用
收藏
页码：777 / 777
页数：1
相关论文
共 50 条
  • [31] Steroid Metabolism in Human Prostate Cancer Tissue: Effect of CYP17 Inhibitors
    Deb, Subrata
    Chin, Mei Yieng
    Pham, Steven
    Adomat, Hans
    Hurtado-Coll, Antonio
    Gleave, Martin
    Guns, Emma S. Tomlinson
    FASEB JOURNAL, 2017, 31
  • [32] CYP17 & SULT1A1 gene polymorphisms in Indian breast cancer
    Chacko P.
    Rajan B.
    Mathew B.S.
    Joseph T.
    Pillai M.R.
    Breast Cancer, 2004, 11 (4) : 380 - 388
  • [33] CYP17 and CYP19 gene polymorphisms in women affected with endometriosis
    Vietri, Maria Teresa
    Cioffi, Michele
    Sessa, Marcella
    Simeone, Serena
    Bontempo, Paola
    Trabucco, Elisabetta
    Ardovino, Mario
    Colacurci, Nicola
    Molinari, Anna Maria
    Cobellis, Luigi
    FERTILITY AND STERILITY, 2009, 92 (05) : 1532 - 1535
  • [34] Detection of CYP17 and CYP19 gene polymorphisms in endometriosis.
    Bozdag, G
    Tuncer, S
    Aksu, T
    Aksu, A
    Saribas, Z
    Gurgan, T
    FERTILITY AND STERILITY, 2005, 84 : S201 - S201
  • [35] Role of CYP17 and SULT1A1 gene polymorphisms in breast cancer
    Rajan, B.
    Chacko, P.
    Pillai, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 102 - 102
  • [36] A polymorphism in CYP17 and endometrial cancer risk
    Haiman, CA
    Hankinson, SE
    Colditz, GA
    Hunter, DJ
    De Vivo, I
    CANCER RESEARCH, 2001, 61 (10) : 3955 - 3960
  • [37] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2:: implication for prostate cancer risk
    Kakinuma, H
    Tsuchiya, N
    Habuchi, T
    Ohyama, C
    Matsuura, S
    Wang, L
    Nakamura, A
    Kato, T
    PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (04) : 333 - 337
  • [38] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk
    H Kakinuma
    N Tsuchiya
    T Habuchi
    C Ohyama
    S Matsuura
    L Wang
    A Nakamura
    T Kato
    Prostate Cancer and Prostatic Diseases, 2004, 7 : 333 - 337
  • [39] Inhibitors of 17α-hydroxylase/17,20-lyase (CYP17):: Potential agents for the treatment of prostate cancer
    Njar, VCO
    Brodie, AMH
    CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (03) : 163 - 180
  • [40] CYP17 genotype and breast cancer risk
    Weston, A
    Pan, CF
    Bleiweiss, IJ
    Ksieski, HB
    Roy, N
    Maloney, N
    Wolff, MS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1998, 7 (10) : 941 - 944
12345